We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy.
- Authors
Fang, Chao; Li, Xiang‐Ping; Gong, Wei‐Jing; Wu, Na‐Yiyuan; Tang, Jie; Yin, Ji‐Ye; Li, Xi; Zhang, Wei; Zhou, Hong‐Hao; Liu, Zhao‐Qian
- Abstract
Platinum-based chemotherapy toxicity severely impedes successful treatment in lung cancer patients. MicroRNAs (miRs) have a significant impact on the occurrence and survival rate of lung cancer. The purpose of this study was to investigate the association between common miRNA variants and platinum-based chemotherapy toxicity in lung cancer patients. A total of eight functional single nucleotide polymorphisms (SNPs) of miRNA were genotyped in 408 lung cancer patients by MALDI-TOF mass spectrometry. All the patients were histologically confirmed as lung cancer, and were treated with platinum-based chemotherapy for at least two cycles. It was found that the polymorphism rs2042553 of miR-5197 had a significant association with overall severe toxicity in both additive (P=.031, odds ratio [OR]=1.41, 95% confidence interval [CI] 1.03-1.93) and dominant (P=.009, OR=1.80, 95% CI 1.16-2.80) models. MiR-605 rs2043556 was significantly related to severe hepatotoxicity in dominant model (P=.022, OR=2.51, 95% CI 1.12-4.14). In addition, rs2910164 of miR-146a had marginal statistical effect on severe hepatotoxicity in additive model (P=.054). The subgroup analyses showed that miR-27a rs895819 was related to gastrointestinal toxicity in age >56 years old, smoking and non-smoking patients. Taken together, our results revealed that polymorphisms of miR-5197, miR-605, miR-146a, and miR-27a contributed to the chemotherapy toxicity of lung cancer, which may serve as a predictive tool for toxicity evaluation of platinum-based chemotherapy in lung cancer patients.
- Subjects
MICRORNA; GENETIC polymorphisms; LUNG cancer; DRUG toxicity; PLATINUM; CHEMOTHERAPY complications; THERAPEUTICS
- Publication
Clinical & Experimental Pharmacology & Physiology, 2017, Vol 44, p21
- ISSN
0305-1870
- Publication type
Article
- DOI
10.1111/1440-1681.12704